Figure 7.

MMP activity from culture media of IL-1β treated human chondrocytes and the inhibitory effects of progrado. Subconfluent human chondrocytes were treated with IL-1β (10 ng/ml) to stimulate the release of matrix metalloproteinases, measured as MMP and MMP-9 using gelatin zymography. Progrado was associated with a dose-dependent inhibition of both MMP-2 and MMP-9 activity. Complete inhibition of MMP-9 was evident at 4 μg/ml, with MMP-2 activity reduced by approximately 90%.